Fig. 7
mPFC D1r pharmacological manipulations impact the effects of ketamine. a FST immobility time 24 h after D1r agonist administration (ANOVA p < 0.05, post-hoc t-test p < 0.05 vs. Veh). b Locomotor activity 24 h after D1r agonist infusion. c Time to feed in the NSF test 48 h after D1r agonist infusion (Mantel–Cox (log rank) overall p < 0.05, Veh vs. 1.0 µg p < 0.05). d FST immobility time 24 h after ketamine treatment with, or without, D1r antagonist (500 ng/side) pretreatment (Factorial ANOVA interaction p < 0.05, post-hoc t-test p < 0.01). e Locomotor activity 24 h after ketamine treatment with, or without, D1r antagonist pretreatment. f NSF time 72 h after treatment with combinations of ketamine and D1r antagonist (Mantel–Cox (log rank) overall p < 0.001, Veh–Veh vs. Veh–Ket p < 0.01); *p < 0.05, **p < 0.01. Error bars represent mean ± SEM. All data points—male
